Literature DB >> 31442839

Magnetic cationic liposomal nanocarriers for the efficient drug delivery of a curcumin-based vanadium complex with anticancer potential.

Eleftherios Halevas1, Barbara Mavroidi2, Claudia H Swanson3, Graham C Smith3, Alexandra Moschona4, Spyros Hadjispyrou5, Athanasios Salifoglou5, Anastasia A Pantazaki6, Maria Pelecanou2, George Litsardakis7.   

Abstract

In this work novel magnetic cationic liposomal nanoformulations were synthesized for the encapsulation of a crystallographically defined ternary V(IV)-curcumin-bipyridine (VCur) complex with proven bioactivity, as potential anticancer agents. The liposomal vesicles were produced via the thin film hydration method employing N-[1-(2,3-dioleoyloxy)propyl]-N,N,N-trimethylammonium (DOTAP) and egg phosphatidylcholine lipids and were magnetized through the addition of citric acid surface-modified monodispersed magnetite colloidal magnetic nanoparticles. The obtained nanoformulations were evaluated for their structural and textural properties and shown to have exceptional stability and enhanced solubility in physiological media, demonstrated by the entrapment efficiency and loading capacity results and the in vitro release studies of their cargo. Furthermore, the generated liposomal formulations preserved the superparamagnetic behavior of the employed magnetic core maintaining the physicochemical and morphological requirements for targeted drug delivery applications. The novel nanomaterials were further biologically evaluated for their DNA interaction potential and were found to act as intercalators. The findings suggest that the positively charged magnetic liposomal nanoformulations can generate increased concentration of their cargo at the DNA site, offering a further dimension in the importance of cationic liposomes as nanocarriers of hydrophobic anticancer metal ion complexes for the development of new multifunctional pharmaceutical nanomaterials with enhanced bioavailability and targeted antitumor activity.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Anticancer potential; DNA interaction; Drug encapsulation; Magnetic cationic liposomes; Targeted drug delivery; Vanadium-curcumin complexes

Mesh:

Substances:

Year:  2019        PMID: 31442839     DOI: 10.1016/j.jinorgbio.2019.110778

Source DB:  PubMed          Journal:  J Inorg Biochem        ISSN: 0162-0134            Impact factor:   4.155


  5 in total

1.  In vitro and in silico evaluation of the inhibitory effect of a curcumin-based oxovanadium (IV) complex on alkaline phosphatase activity and bacterial biofilm formation.

Authors:  G Katsipis; V Tsalouxidou; E Halevas; E Geromichalou; G Geromichalos; A A Pantazaki
Journal:  Appl Microbiol Biotechnol       Date:  2020-11-16       Impact factor: 4.813

Review 2.  Hybrid Nanosystems for Biomedical Applications.

Authors:  Joshua Seaberg; Hossein Montazerian; Md Nazir Hossen; Resham Bhattacharya; Ali Khademhosseini; Priyabrata Mukherjee
Journal:  ACS Nano       Date:  2021-01-26       Impact factor: 18.027

3.  Modification of radiosensitivity by Curcumin in human pancreatic cancer cell lines.

Authors:  Katharina Schwarz; Sophie Dobiasch; Lily Nguyen; Daniela Schilling; Stephanie E Combs
Journal:  Sci Rep       Date:  2020-03-02       Impact factor: 4.379

4.  Tris(2-Pyridylmethylamine)V(O)2 Complexes as Counter Ions of Diprotonated Decavanadate Anion: Potential Antineoplastic Activity.

Authors:  Nidia D Corona-Motolinia; Beatriz Martínez-Valencia; Lisset Noriega; Brenda L Sánchez-Gaytán; Francisco J Melendez; Amalia García-García; Duane Choquesillo-Lazarte; Antonio Rodríguez-Diéguez; María Eugenia Castro; Enrique González-Vergara
Journal:  Front Chem       Date:  2022-02-16       Impact factor: 5.221

5.  The liposomal delivery of hydrophobic oxidovanadium complexes imparts highly effective cytotoxicity and differentiating capacity in neuroblastoma tumour cells.

Authors:  Elsa Irving; Aristides D Tagalakis; Ruhina Maeshima; Stephen L Hart; Simon Eaton; Ari Lehtonen; Andrew W Stoker
Journal:  Sci Rep       Date:  2020-10-07       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.